List of Xelpros drug patents

Xelpros is owned by Sun Pharm.

Xelpros contains Latanoprost.

Xelpros has a total of 2 drug patents out of which 0 drug patents have expired.

Xelpros was authorised for market use on 12 September, 2018.

Xelpros is available in emulsion;ophthalmic dosage forms.

Xelpros can be used as reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

The generics of Xelpros are possible to be released after 12 September, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539262 SUN PHARM Ophthalmic composition comprising a prostaglandin
Oct, 2028

(5 years from now)

US9629852 SUN PHARM Ophthalmic composition comprising a prostaglandin
Sep, 2029

(6 years from now)

Drugs and Companies using LATANOPROST ingredient

Market Authorisation Date: 12 September, 2018

Treatment: Reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic